Top Links

Articles Related to leukemia

The Impact of Exploring Chromosome Philadelphia like on the Prognosis of Children and Teenager ALL

Acute lymphoblastic leukemia (ALL) is considered as the most common pediatric malignancy with 80% of frequency in children between 1 and 10 years old. With the evolution of science, improved diagnosis and adapted treatment, all survival rates increased to a possibility of 80%. Philadelphia chromosome like acute lymphoblastic leukemia (Ph-Like ALL) is a recent genetic discovery characterized by a gene expression profile and high frequency of IKZF1 gene alteration similar to that of BCR-ABL1 positive ALL with a poor outcome.
View complete article: PDF  |  Full-text

A Chronic Myeloid Leukemia Case Showing Spontaneous Ph-positive Clone Regression and Bone Marrow Hypoplasia after a Short Treatment with Dasatinib

Dasatinib is an orally bioavailable second generation TKI, more potent than imatinib. Bone marrow aplasia or hypoplasia secondary to TKI therapy is an uncommon adverse event. We report here the first case of chronic myeloid leukemia in chronic phase shortly treated with dasatinib that developed a prolonged bone marrow hypoplasia with concomitant response on the hematological disease with gradual improvement of the cytogenetic and molecular response after dasatinib discontinuation, without use of any other TKI therapy.
View complete article: PDF  |  Full-text

Adverse Drug Events and Predictors of One Year Survival among Adult Patients with Acute Myeloid Leukemia in a Kenyan Tertiary Health Facility

Treatment of acute myeloid leukemia is a challenge because of the adverse drug events associated with therapy and the heterogeneous nature of the subtypes. Research on improving overall survival of patients based on different regimens, reduction of adverse dug events, clinical characteristics and the type of acute myeloid leukemia is critical.
View complete article: PDF  |  Full-text

Blastic Plasmacytoid Dendritic Cell Neoplasm Presenting as a Harbinger of Acute Myeloid Leukemia

A 51 year old female was referred to our dermatology clinic for a rapidly growing lump on head of 6 weeks duration. On examination we observed a 15 cm diameter erythematous crusted tumor on the forehead with significant bilateral cervical lymphadenopathy. An excision biopsy of the tumor revealed a malignant high grade diffuse undifferentiated infiltrating neoplasm involving the skin and subcutaneous tissue.
View complete article: PDF  |  Full-text

Treatment of Chronic Myeloid Leukemia with Imatinib: A Study of 48 Cases in Burkina Faso

The purpose of the study was to evaluate the management of patients treated with Imatinib for Chronic Myeloid Leukemia (CML) in the Department of Clinical Hematology of the Yalgado OUEDRAOGO University Hospital in Ouagadougou, Burkina Faso.
View complete article: PDF  |  Full-text

Degree of Malignancy of T-Cell Acute Lymphocytic Leukemia Related to Autofluorescence in an EL4-Based Model

T cell acute lymphocytic leukemia (T-ALL) is an aggressive hematologic malignancy in terms of its pathology and populations. It is important to understand the phenomenon of autofluorescence in living cells because normal and cancer cells can be distinguished by this feature. However, the autofluorescence link to T-ALL is poorly understood.
View complete article: PDF  |  Full-text

How to select Tyrosine Kinase Inhibitor for the patients with newly diagnosed Chronic Myeloid Leukemia?

The clinical outcomes of chronic myeloid leukemia (CML) have been improved by tyrosine kinase inhibitors (TKIs). However, there is no established consensus for TKI selection in de novo CML. We investigated TKI treatment patterns in a real-world setting. Among 95 chronic-phase CML patients, 44% were initiated treatment with imatinib, 26% with dasatinib, and 30% with nilotinib. Our data suggest that imatinib remains applicable and that dasatinib has a favorable therapeutic effect, although pleural effusion can arise. Nilotinib was the most prevalent TKI as the treatment-associated adverse events were deemed more manageable than those associated with imatinib and dasatinib.
View complete article: PDF  |  Full-text

Tomotherapy Treatment of Chronic Lymphocytic Leukemia and Ocular Lymphoma

A sixty-five-years-old male patient with history of non-Hodgkin’s lymphoma of the right orbit and a fifty-years-old female patient with chronic lymphocytic leukemia with peripheral lymphocytosis were treated on TomoTherapy. In the first case, a 1 cm beam was used for planning a delivery of 30.6 Gy in 17 fractions with a sequential boost of 9 Gy in 5 fractions. Tumor involvement of the ipsilateral lens and lacrimal gland in the planning target volume necessitated a compromise between preserving patient’s vision and delivery of tumoricidal dose to the target. In the second case, 30 Gy in 20 fractions delivery was planned with a 2.5 cm beam. The tumor extended anteriorly and this technique allowed sparing more orbital tissue and required a high modulation factor.
View complete article: PDF  |  Full-text

Prevalence of the different FAB sub type of Acute Myeloid Leukemia related to hematological parameters in Sudanese

Acute myeloid leukemia (AML) is a heterogeneous disease. Therefore, various parameters are needed to classify this disease into subtypes. The commonly used method for diagnosis and classification is based on FAB criteria using morphology and cytochemical stains. For some of the categories, immunopheno typing is necessary. The aim of present study is to determine the frequency of various sub-types in acute myeloid leukemia using FAB criteria in our Sudanese population. This will aid in the correct diagnosis of acute leukemia and hence proper management of the patients.
View complete article: PDF  |  Full-text

Acute Myeloid Leukemia Mimicking as Acute Megakaryoblastic Leukemia

Down syndrome or constitutional trisomy 21 was linked to leukemia for the first time in a case report published in 1930 since then, down syndrome has been recognized as one of the most important leukemia – predisposing syndromes and patients with down syndrome and leukemia have unique clinical features and significant differences in treatment response toxicity profiles compared to patients without down syndrome.
View complete article: PDF  |  Full-text

Responses and Survival under Pegylated Interferon α2a Treatment for Patients with Post-MPN Acute Myeloid Leukemia and Acute Panmyelosis with Myelofibrosis

We report here for the first time the efficacy of pegylated interferon α2a (Peg-Ifn) as a therapy for patients with myelofibrosis and high blast counts. We treated four patients who were in an accelerated phase of myeloproliferative neoplasms or acute panmyelosis with myelofibrosis using only this drug.
View complete article: PDF  |  Full-text

Observations on Aeromonas Infection in 7 Patients with Acute Leukemia

Aeromonas infections in humans are becoming increasingly frequent. They have the potential to infect humans and are associated with a variety of illnesses, such as enterocolitis, septicemia, skin and soft tissue infectious and peritonitis.
View complete article: PDF  |  Full-text

Microwave and Magnetic (M2 ) Proteomics of Childhood B-ALL

We hypothesized that quantitative tandem mass spectrometry-based proteomics, incorporating rapid microwave and magnetic sample preparation (M2 proteomics), might enable relative protein expression to be correlated to childhood B-precursor acute lymphoblastic leukemia (B-ALL) cytogenetic subtypes, corresponding to low-risk (ETV6-RUNX1) and high-risk (MLL-R) subtypes.
View complete article: PDF  |  Full-text

Vasculitis Associated with Chronic Lymphocytic Leukemia

A patient is present who has chronic lymphocytic leukemia (CLL) and developed a vasculitis involving the skin and large vessels along with immune complex mediated glomerulosclerosis. Both vasculitis and immune complex nephritis are rare manifestations of CLL.
View complete article: PDF  |  Full-text

Development of the Analytical Model for the Assessment of the Efficiencies of Different Therapeutic Modalities in Leukemia

Different therapeutic regimes like chemotherapy, cytokine based immunotherapy and/or stem cell transplantation are generally be the suggested options for treatment of leukemia. However, the selection of the best therapeutic strategy for an individual patient remains uncertain till now
View complete article: PDF  |  Full-text


Editorial Board Members Related to leukemia

Jonathan Scott Harrison

Professor
Division of Hematology/Medical Oncology University of Missouri
United States

Julie Teruya-Feldstein

Director
Hematopathology
Immunohistochemistry Laboratory
United States

Grant Dewson

Laboratory Head
Cell Signalling and Cell Death Division
Walter & Eliza Hall Institute of Medical Research
Australia

Khaldon Bodoor

Associate Professor
Department of Biotechnology and Genetic Engineering
Jordan University of Science and Technology
Jordan

Rammurti T. Kamble

Professor of Medicine
Baylor College of Medicine
United States

Jeffrey Michael Venstrom

Assistant Professor
Department of Medicine
University of California, San Francisco
United States

Jason X. Cheng

Assistant Professor
Department of Pathology, Hematopathology
University of Chicago
United states

Anthony Joseph Berdis

Assistant Professor
Departments of Chemistry and Biology
Cleveland State University
United States

PREET M. CHAUDHARY

Professor
Department of Medicine
University of Southern California
United States

Yun Dai

Associate Professor
Department of Medicine
Virginia Commonwealth University
United States
Submit Manuscript